Date:Aug. 31 st , 2022
Your Name: Eisuke Tomiyama
Manuscript Title:_ Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in
the era of targeted therapy: A narrative review
Manuscript number (if known):_ <u>TAU-22-457</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone
5	Dayment or honoraria for	X None
Э	Payment or honoraria for lectures, presentations,	X_None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	XNone
	testimony	
7	Support for attending	X None
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
^	Double in a biomana a Doba	W. Alara
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		V. None
11	Stock or stock options	XNone
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
Ple	ease summarize the above co	onflict of interest in the following box:
	Nama.	
	None.	

Date:Aug. 30 th , 2022
Your Name:_Kazutoshi Fujita
Manuscript Title: <u>Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in</u>
the era of targeted therapy: A narrative review
Manuscript number (if known):_ TAU-22-457

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_x_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Pfizer	Educational global grand
3	Royalties or licenses	_xNone	
4	Consulting fees	_xNone	

5	Payment or honoraria for	Pfizer	Honoraria for lectures
	lectures, presentations,	Janssen Pharma	Honoraria for lectures
	speakers bureaus,	Astrazeneca	Honoraria for lectures
	manuscript writing or	Astellas	Honoraria for lectures
	educational events	ONO Pharmaceutical	Honoraria for lectures
		Bristol Myers Squibbs	Honoraria for lectures
6	Payment for expert	_xNone	
	testimony		
7	Support for attending	xNone	
	meetings and/or travel		
8	Patents planned, issued or	_xNone	
	pending		
9	Participation on a Data	Astellas	Advisory board
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x_None	
12	Descipt of agricument	y None	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author receives grants from Pfizer.

The author receives honoraria for lectures from Pfizer, Janssen Pharma, Astrazeneca, Astellas, ONO Pharmaceutical, and Bristol Myers Squibbs.

The author participates advisory board of Astellas.

Please place an "X" next to the following statement to indicate your agreement:

Date:Aug. 31 st , 2022
Your Name: Mamoru Hashimoto
Manuscript Title:_ Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in
the era of targeted therapy: A narrative review
Manuscript number (if known):_ <u>TAU-22-457</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone
5	Dayment or honoraria for	X None
Э	Payment or honoraria for lectures, presentations,	X_None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	XNone
	testimony	
7	Support for attending	X None
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
^	Double in a big on a Date	W. Alara
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		V. None
11	Stock or stock options	XNone
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
Ple	ease summarize the above co	onflict of interest in the following box:
	Nama.	
	None.	

Date:Aug. 31 st , 2022	
Your Name: Shogo Adomi	
Manuscript Title: Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer	in
the era of targeted therapy: A narrative review	
Manuscript number (if known):_ TAU-22-457	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone
5	Dayment or honoraria for	X None
Э	Payment or honoraria for lectures, presentations,	X_None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	XNone
	testimony	
7	Support for attending	X None
	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
^	Double in a big on a Date	W. Alara
9	Participation on a Data Safety Monitoring Board or	XNone
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		V. None
11	Stock or stock options	XNone
12	Receipt of equipment,	X_None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
Ple	ease summarize the above co	onflict of interest in the following box:
	Nama.	
	None.	

Date:Aug. 31 st , 2022
Your Name: Atsunari Kawashima
Manuscript Title: <u>Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer ir</u>
the era of targeted therapy: A narrative review
Manuscript number (if known):_ <u>TAU-22-457</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone			
5	Dayment or honoraria for	X None			
Э	Payment or honoraria for lectures, presentations,	X_None			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert testimony	XNone			
	testimony				
7	Support for attending	X None			
	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
^	Double in a big on a Date	W. Alara			
9	Participation on a Data Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11		V. None			
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
	Nama.				
	None.				

Date:Aug. 31 st , 2022
Your Name: <u>Takafumi Minami</u>
Manuscript Title:_ Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in
the era of targeted therapy: A narrative review
Manuscript number (if known):_ <u>TAU-22-457</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone			
5	Dayment or honoraria for	X None			
Э	Payment or honoraria for lectures, presentations,	X_None			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert testimony	XNone			
	testimony				
7	Support for attending	X None			
	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
^	Double in a big on a Date	W. Alara			
9	Participation on a Data Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11		V. None			
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
	Nama.				
	None.				

Date:Aug. 31 st , 2022
Your Name: Kazuhiro Yoshimura
Manuscript Title: <u>Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer i</u>
the era of targeted therapy: A narrative review
Manuscript number (if known):_ <u>TAU-22-457</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone			
5	Dayment or honoraria for	X None			
Э	Payment or honoraria for lectures, presentations,	X_None			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert testimony	XNone			
	testimony				
7	Support for attending	X None			
	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
^	Double in a big on a Date	W. Alara			
9	Participation on a Data Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11		V. None			
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
	Nama.				
	None.				

Date: Aug. 30 th ,2022				
Your Name:_Hirotsugu Uemura				
Manuscript Title: Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in				
the era of targeted therapy: A narrative review				
Manuscript number (if known):_ TAU-22-457				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_x_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Ono pharma Astrazeneca Astellas	Research grant Research grant Research grant
3	Royalties or licenses	_x_None	
4	Consulting fees	_x_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Pfizer Janssen Pharma Merck BioPharma MSD ONO Pharmaceutical Bristol Myers Squibbs	Honoraria for lectures and manuscript writing Honoraria for lectures Honoraria for lectures and manuscript writing Honoraria for lectures Honoraria for lectures and manuscript writing Honoraria for lectures
6	Payment for expert testimony	_x_None	
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or pending	_x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_x_None	
11	Stock or stock options	_x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_x_None	
13	Other financial or non- financial interests	_x_None	

Please summarize the above conflict of interest in the following box:

The author receives grants from Ono pharma, Astrazeneca, and Astellas.

The author receives payment or honoraria for lectures from Pfizer, Janssen Pharma, Merck BioPharma, MSD, ONO Pharmaceutical, and Bristol Myers Squibbs.

Please place an "X" next to the following statement to indicate your agreement:

Date:Aug. 31 st , 2022					
Your Name: Norio Nonomura					
Manuscript Title:_ Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in					
e era of targeted therapy: A narrative review					
Manuscript number (if known):_ TAU-22-457					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		needed)			
	Time frame: Since the initial planning of the work				
1	All support for the present	XNone			
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article				
	processing charges, etc.) No time limit for this item.				
	No time limit for this item.				
	Time frame: past 36 months				
2	Grants or contracts from	XNone			
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	XNone			

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	Pfizer Janssen Pharma Merck Biopharma AstraZeneca MSD ONO Pharmaceutical Bristol Myers SquibbXNone	Honoraria for lectures
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Pfizer Bristol Myers Squibb	Advisory board Advisory board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

The author receives payment or honoraria for lectures from Pfizer, Janssen Pharma, Merck BioPharma, AstraZeneca, MSD, ONO Pharmaceutical, and Bristol Myers Squibb.

The author participates advisory board of Pfizer and Bristol Myers Squibb.

Please place an "X" next to the following statement to indicate your agreement: